Compare GLUE & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLUE | OCSL |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2021 | 2008 |
| Metric | GLUE | OCSL |
|---|---|---|
| Price | $16.03 | $12.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $19.50 | $14.33 |
| AVG Volume (30 Days) | ★ 976.6K | 759.5K |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 12.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.25 | ★ 0.39 |
| Revenue | $181,538,000.00 | ★ $316,801,000.00 |
| Revenue This Year | $81.52 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $62.71 | ★ $32.56 |
| Revenue Growth | ★ 1112.27 | N/A |
| 52 Week Low | $3.50 | $12.44 |
| 52 Week High | $19.17 | $16.29 |
| Indicator | GLUE | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 30.75 |
| Support Level | $14.64 | $13.53 |
| Resistance Level | $19.17 | $12.99 |
| Average True Range (ATR) | 1.23 | 0.20 |
| MACD | -0.29 | -0.10 |
| Stochastic Oscillator | 30.91 | 5.58 |
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.